1. GPCR/G Protein
    Immunology/Inflammation
  2. CXCR

Danirixin (Synonyms: GSK1325756; GSK-1325756; GSK 1325756)

Cat. No.: HY-19768
Handling Instructions

Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.

For research use only. We do not sell to patients.
Danirixin Chemical Structure

Danirixin Chemical Structure

CAS No. : 954126-98-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO $340 In-stock
1 mg $150 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.

IC50 & Target

IC50: 12.5 nM (CXCL8)[1]

In Vitro

Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02130193 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive February 13, 2014 Phase 2
NCT03170232 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive September 11, 2017 Phase 2
NCT02453022 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive May 18, 2015 Phase 1
NCT03034967 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive April 26, 2017 Phase 2
NCT02927431 GlaxoSmithKline Virus Diseases January 1, 2017 Phase 2
NCT02469298 GlaxoSmithKline Virus Diseases June 2015 Phase 2
NCT02201303 GlaxoSmithKline Infections, Respiratory Syncytial Virus January 13, 2014 Phase 1
NCT01209104 GlaxoSmithKline Nutritional Status April 14, 2010 Phase 1
NCT01209052 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive October 15, 2009 Phase 1
NCT02169583 GlaxoSmithKline Infections, Respiratory Tract June 12, 2014 Phase 1
NCT01453478 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive October 12, 2011 Phase 1
NCT01267006 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive November 2010 Phase 1
NCT03136380 GlaxoSmithKline Pulmonary Disease, Chronic Obstructive May 10, 2017 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.2630 mL 11.3148 mL 22.6296 mL
5 mM 0.4526 mL 2.2630 mL 4.5259 mL
10 mM 0.2263 mL 1.1315 mL 2.2630 mL
References
M.Wt

441.9

Formula

C₁₉H₂₁ClFN₃O₄S

CAS No.

954126-98-8

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 8 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Danirixin
Cat. No.:
HY-19768
Quantity: